CC-5013
Sponsors
Celgene, Celgene Corporation, M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic
Conditions
AmyloidosisCrohn's DiseaseMalignant MelanomaMelanomaMultiple MyelomaMyelodysplastic SyndromeMyelodysplastic SyndromesMyelofibrosis
Phase 1
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
CompletedNCT00091624
Start: 2003-03-31End: 2007-09-30Updated: 2016-12-01
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
CompletedNCT00153933
Start: 2004-08-31End: 2014-07-31Updated: 2016-01-25
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
CompletedNCT00179712
Start: 2005-04-30End: 2006-11-30Target: 60Updated: 2016-12-01
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
CompletedNCT00179608
Start: 2005-09-01End: 2007-06-01Target: 28Updated: 2019-11-08
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
TerminatedNCT00179751
Start: 2005-04-30End: 2006-08-31Target: 50Updated: 2005-11-07
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
TerminatedNCT00179725
Start: 2005-11-30End: 2007-06-30Target: 60Updated: 2006-04-12
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
TerminatedNCT00179699
Start: 2005-09-30End: 2006-11-30Target: 40Updated: 2005-11-07
Phase 2
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
CompletedNCT00044382
Start: 2002-02-01End: 2007-01-30Target: 25Updated: 2019-11-08
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
CompletedNCT00051116
Start: 2002-05-31End: 2006-10-31Updated: 2009-09-23
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
CompletedNCT00064974
Start: 2003-06-30End: 2007-02-28Updated: 2013-04-04
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
CompletedNCT00065351
Start: 2003-07-01End: 2007-03-01Updated: 2019-11-12
A Phase II Study of CC-5013 in Myelofibrosis
CompletedNCT00087672
Start: 2004-07-31End: 2009-02-28Updated: 2012-08-07
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
CompletedNCT00166413
Start: 2005-04-30Target: 38Updated: 2011-05-06
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
CompletedNCT00179686
Start: 2005-03-31End: 2006-07-31Target: 40Updated: 2006-12-20
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
CompletedNCT00446433
Start: 2002-03-31End: 2003-12-31Target: 90Updated: 2016-12-01
Phase 3
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
CompletedNCT00056160
Start: 2003-01-01End: 2008-10-01Updated: 2017-10-19
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
CompletedNCT00057616
Start: 2002-10-01End: 2005-07-15Target: 274Updated: 2019-11-08
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
CompletedNCT00622336
Start: 2003-04-01End: 2013-11-25Updated: 2019-11-20